Profile data is unavailable for this security.
About the company
Philogen SpA is an Italy-based company operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It focuses mainly on discovering and developing targeted anti-cancer drugs, using high-affinity ligands for tumor markers. These ligands are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The Company’s products primarily address applications in the oncology field, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. It has four anti-cancer antibody derivatives in clinical studies, one of which has completed a Phase III trial. The Company is active in the Discovery Unit through its subsidiary Philochem AG.
- Revenue in EUR (TTM)78.72m
- Net income in EUR45.91m
- Incorporated--
- Employees193.00
- LocationPhilogen SpAVia Bellaria, 35SOVICILLE 53018ItalyITA
- Phone+39 577206941
- Fax+39 57742151
- Websitehttps://www.philogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saniona AB | 69.92m | 53.95m | 315.53m | 31.00 | 5.29 | 4.86 | 5.78 | 4.51 | 4.60 | 4.60 | 5.98 | 5.00 | 1.75 | -- | 121.92 | 33,782,040.00 | 135.23 | -38.47 | 170.81 | -45.71 | 90.13 | -55.15 | 77.16 | -156.43 | -- | -- | 0.0004 | -- | 1,887.36 | 115.50 | 296.96 | -- | -48.69 | -- |
| Hansa Biopharma AB | 16.80m | -60.31m | 346.74m | 133.00 | -- | -- | -- | 20.64 | -8.90 | -8.90 | 2.45 | -6.62 | 0.2124 | 26.30 | 1.00 | 1,323,052.00 | -76.25 | -54.70 | -133.86 | -66.53 | 59.47 | 59.67 | -358.96 | -643.96 | 1.10 | -77.82 | 2.54 | -- | 27.76 | 119.48 | 2.94 | -- | -49.20 | -- |
| Puretech Health PLC | 5.40m | 42.80m | 349.47m | 56.00 | 8.26 | 1.09 | 11.71 | 64.75 | 0.1523 | 0.1523 | 0.0195 | 1.15 | 0.0113 | -- | 2.81 | 83,860.19 | 5.63 | -3.27 | 6.57 | -3.83 | -- | -- | 498.87 | -253.25 | -- | -- | 0.0537 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
| Formycon AG | 51.78m | -169.77m | 406.48m | 245.00 | -- | 0.995 | -- | 7.85 | -9.60 | -9.60 | 2.93 | 23.12 | 0.0613 | 31.72 | 1.91 | 207,112.00 | -20.09 | -1.47 | -21.17 | -1.58 | -0.9927 | 25.54 | -327.88 | -13.00 | 1.51 | -1.27 | 0.0244 | -- | -10.32 | 15.48 | -265.81 | -- | 96.87 | -- |
| Newron Pharmaceuticals SpA | 60.12m | 25.43m | 418.97m | 22.00 | 15.28 | 263.07 | 16.36 | 6.97 | 1.25 | 1.25 | 2.85 | 0.0726 | 1.39 | -- | 11.69 | 2,494,771.00 | 58.67 | -23.70 | 123.93 | -32.05 | 98.17 | 97.14 | 42.30 | -69.33 | -- | 8.56 | 0.9708 | -- | 467.41 | 48.83 | 197.65 | -- | -23.92 | -- |
| Philogen SpA | 78.72m | 45.91m | 619.95m | 193.00 | 18.64 | 6.78 | 12.40 | 7.88 | 1.14 | 1.14 | 1.96 | 3.13 | 0.5961 | 5.65 | 21.87 | 430,158.50 | 34.77 | 0.7964 | 40.11 | 0.8907 | 74.04 | 58.86 | 58.33 | 3.70 | 5.52 | -- | 0.0837 | -- | 219.91 | 42.46 | 835.14 | 100.38 | 10.46 | -- |
| Valneva SE | 179.91m | -102.16m | 693.68m | 700.00 | -- | 4.60 | -- | 3.86 | -0.5807 | -0.5807 | 1.08 | 0.8762 | 0.3729 | 1.61 | 7.13 | 258,867.60 | -21.18 | -14.46 | -28.97 | -23.62 | 45.36 | 34.12 | -56.78 | -34.54 | 1.36 | -3.61 | 0.5655 | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
| Basilea Pharmaceutica AG Allschwil | 258.75m | 79.59m | 827.33m | 180.00 | 10.83 | 6.75 | 10.13 | 3.20 | 5.23 | 5.23 | 17.03 | 8.40 | 1.08 | 1.66 | 10.57 | 1,440,305.00 | 33.21 | 7.08 | 39.78 | 11.18 | 81.04 | 82.50 | 30.76 | 9.96 | 5.67 | 31.61 | 0.4428 | -- | 32.30 | 9.19 | 642.45 | -- | 34.71 | -- |
| Nanobiotix SA | -14.04m | -51.64m | 868.32m | 103.00 | -- | -- | -- | -- | -1.09 | -1.09 | -0.2962 | -1.43 | -0.213 | -- | -- | -130,037.00 | -78.34 | -54.39 | -839.67 | -90.60 | -- | -- | -- | -1,326.20 | -- | -7.32 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
| Gubra A/S | 352.99m | 233.76m | 899.41m | 275.00 | -- | 5.53 | -- | 2.55 | -1.03 | -1.03 | 161.54 | 74.35 | 1.50 | -- | 68.31 | 11,174,780.00 | 99.21 | -- | 190.28 | -- | 3.52 | -- | 66.22 | -- | -- | -- | 0.0709 | -- | 29.63 | -- | 18.03 | -- | -- | -- |
Data as of Feb 09 2026. Currency figures normalised to Philogen SpA's reporting currency: Euro EUR
7.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fideuram Asset Management SGR SpAas of 31 Dec 2025 | 646.13k | 2.21% |
| Mediolanum Gestione Fondi SGRpAas of 30 Sep 2025 | 378.07k | 1.29% |
| Ersel Asset Management SGR SpAas of 30 Jun 2025 | 281.00k | 0.96% |
| Arca Fondi SGR SpAas of 30 Dec 2025 | 263.34k | 0.90% |
| Amundi SGR SpAas of 28 Jun 2024 | 190.00k | 0.65% |
| CARTHESIO SAas of 30 Jun 2025 | 145.75k | 0.50% |
| Eurizon Capital SGR SpAas of 28 Nov 2025 | 116.23k | 0.40% |
| Schroder Investment Management Ltd.as of 31 Dec 2025 | 110.05k | 0.38% |
| Azimut Capital Management SGR SpAas of 30 Jan 2026 | 62.62k | 0.21% |
| Kairos Partners SGR SpAas of 30 Jun 2025 | 54.33k | 0.19% |
More ▼
Data from 30 Jun 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
